1. Neurological Disease

Neurological Disease

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15419A
    RS-127445 199864-87-4 99.95%
    RS-127445 is a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist with a pKi of 9.5. RS-127445 shows 1000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites.
    RS-127445
  • HY-154980
    NXE0041178 2642079-89-6 99.97%
    NXE0041178 (Procedure 1) is a GPR52 receptor modulator with the potential to study neuropsychiatric diseases.
    NXE0041178
  • HY-155021
    PROTAC α-synuclein degrader 5 2781922-42-5 99.95%
    PROTAC α-synuclein degrader 5 is a highly selective small-molecule degrader (PROTAC) of α-synuclein aggregates, with a DC50 of 7.51 μM and the highest degradation rate Dmax of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research.
    PROTAC α-synuclein degrader 5
  • HY-160267
    iPAF1C 950403-60-8 99.59%
    iPAF1C is a inhibitor of the polymerase-associated factor 1 complex (PAF1C) with specific targeting to the PAF1 binding groove of CTR9 (a key subunit of PAF1C). iPAF1C disrupts PAF1C assembly by interfering with the PAF1-CTR9 interaction. iPAF1C selectively impairs BRD4-mediated recruitment of PAF1 to chromatin at hypoxia-responsive genes and inhibits RNA polymerase II (RNAPII) pause release. iPAF1C increases the population of HIV-1 NL4.3 Nef-IRES-GFP infected primary human CD4+T cells in a dose-dependent manner. PAF1C can be used for the study of infection and diseases associated with abnormal hypoxic adaptation (e.g., cancers, neurological disorders).
    iPAF1C
  • HY-16637D
    Folic acid disodium 29704-76-5 99.15%
    Folic acid disodium (Vitamin B9 disodium; Vitamin M disodium) is an orally active disodium salt form of Folic acid (HY-16637) with an intrinsic dissolution rate (IDR) of 4.96·105 g/s. Folic acid disodium serves as cofactor in single-carbon transfer reactions and exhibits protective effects against neural tube defects, ischemic events, and cancer. Folate acid disodium overload leads to impaired brain development in embryogenesis and promotes growth of precancerous altered cells. Folic acid deficiency leads to megaloblastic anemia.
    Folic acid disodium
  • HY-169996
    NP3-253 2557349-50-3 99.78%
    NP3-253 is an NLRP3 inhibitor with oral activity and blood-brain barrier permeability, and NP3-253 can serve as a tool to further investigate the biological characteristics of NLRP3 in peripheral and neuroinflammatory model.
    NP3-253
  • HY-170621
    STAT1/3-IN-1 2958649-56-2 98%
    STAT1/3-IN-1 (Compound 6k) is a STAT1/3 phosphorylation inhibitor. STAT1/3-IN-1 inhibits the phosphorylation and nuclear translocation of STAT1/3. STAT1/3-IN-1 also inhibits inflammatory enzymes iNOS and COX-2. STAT1/3-IN-1 demonstrates anti-inflammatory effect (reduction of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α) without significant cytotoxicity.
    STAT1/3-IN-1
  • HY-70057A
    Safinamide mesylate 202825-46-5 99.07%
    Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 μM) over MAO-A (IC50=580 nM). Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8?μM) than at resting (IC50=262?μM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al.
    Safinamide mesylate
  • HY-B0653A
    Levobupivacaine hydrochloride 27262-48-2 99.86%
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
    Levobupivacaine hydrochloride
  • HY-B1777A
    Spermine tetrahydrochloride 306-67-2 98.0%
    Spermine tetrahydrochloride is a polyamine nitric oxide donor that can provide nitric oxide to platelets and inhibit platelet activation to a certain extent concentration-dependently. Spermine tetrahydrochloride occurs in mammalian tissues, plants, bacteria, ribosomes and bacteriophage. Spermine tetrahydrochloride inhibits primary human embryo lung fibroblasts in vitro. Spermine is a natural antioxidant and anti-inflammatory agent. Spermine is known to inhibit some bacterial cultures, especially strains of Staphylococcus aureus. Spermine induces neurotoxicity in the striarum dose-dependently. Spermine can reversibly inhibits DNA synthetic response, mixed lymphocyte response and the induction of cytolytic lymphocyte response in primary cultures of murine spleen cells.
    Spermine tetrahydrochloride
  • HY-N0110B
    Palmatine hydroxide 131-04-4 99.64%
    Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
    Palmatine hydroxide
  • HY-N0926A
    Columbamine chloride 1916-10-5 99.62%
    Columbamine (Columbamin; Dehydroisocorypalmine) chloride is an organic heterotetracyclic alkaloid extracted from plants. Columbamine chloride is a metabolite of Berberine (HY-N0716). Columbamine chloride inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM). Columbamine chloride induces apoptosis in cancer cells. Columbamine chloride can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study.
    Columbamine chloride
  • HY-P0252A
    α-MSH TFA 171869-93-5 98.54%
    α-MSH (α-Melanocyte-Stimulating Hormone) TFA, an endogenous neuropeptide, is an endogenous melanocortin receptor 4 (MC4R) agonist with anti-inflammatory and antipyretic activities. α-MSH TFA is a post-translational derivative of pro-opiomelanocortin (POMC).
    α-MSH TFA
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable 98.37%
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth.
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-P1422A
    Spadin TFA 99.73%
    Spadin TFA, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with an IC50 value of 10 nM. Spadin TFA enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin TFA can be used for antidepressant research.
    Spadin TFA
  • HY-P4882A
    (Pyr3)-Amyloid β-Protein (3-42) (TFA) 98.20%
    (Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits.
    (Pyr3)-Amyloid β-Protein (3-42) (TFA)
  • HY-P99105
    Anselamimab 2414866-63-8 98.96%
    Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis.
    Anselamimab
  • HY-101365A
    RS-102221 hydrochloride 187397-18-8 98.03%
    RS-102221 hydrochloride is a selective 5-HT2C receptor antagonist (Ki=10 nM). RS-102221 hydrochloride shows nearly 100-fold selectivity for the 5-HT2C receptor as compared to the 5-HT2A and 5-HT2B receptors. RS-102221 hydrochloride can promote the differentiation of new nerve cells. RS-102221 hydrochloride increases food-intake and weight-gain in rats.
    RS-102221 hydrochloride
  • HY-101374A
    AGN 192403 hydrochloride 1021868-90-5 99.00%
    AGN 192403 (BRD4780) hydrochloride is an I1-Imidazoline receptor antagonist for cardiovascular and neurological research.
    AGN 192403 hydrochloride
  • HY-101445B
    (S)-Trolox 53174-06-4 99.36%
    (S)-Trolox is an analogue of vitamin E, in which the phytyl chain is replaced with a carboxyl group. (S)-Trolox is frequently used as a model compound for studies of structural features, as well as a standard for evaluation of antioxidant activity. (S)-Trolox has potent and specific neuroprotective and antioxidant effects.
    (S)-Trolox
Cat. No. Product Name / Synonyms Application Reactivity